4.2 Article

Addressing potential prior-data conflict when using informative priors in proof-of-concept studies

Journal

PHARMACEUTICAL STATISTICS
Volume 15, Issue 1, Pages 28-36

Publisher

WILEY-BLACKWELL
DOI: 10.1002/pst.1722

Keywords

Bayesian analysis; informative prior; prior-data conflict; mixture prior; robust prior; proof-of-concept

Ask authors/readers for more resources

Bayesian methods are increasingly used in proof-of-concept studies. An important benefit of these methods is the potential to use informative priors, thereby reducing sample size. This is particularly relevant for treatment arms where there is a substantial amount of historical information such as placebo and active comparators. One issue with using an informative prior is the possibility of a mismatch between the informative prior and the observed data, referred to as prior-data conflict. We focus on two methods for dealing with this: a testing approach and a mixture prior approach. The testing approach assesses prior-data conflict by comparing the observed data to the prior predictive distribution and resorting to a non-informative prior if prior-data conflict is declared. The mixture prior approach uses a prior with a precise and diffuse component. We assess these approaches for the normal case via simulation and show they have some attractive features as compared with the standard one-component informative prior. For example, when the discrepancy between the prior and the data is sufficiently marked, and intuitively, one feels less certain about the results, both the testing and mixture approaches typically yield wider posterior-credible intervals than when there is no discrepancy. In contrast, when there is no discrepancy, the results of these approaches are typically similar to the standard approach. Whilst for any specific study, the operating characteristics of any selected approach should be assessed and agreed at the design stage; we believe these two approaches are each worthy of consideration. Copyright (c) 2015 John Wiley & Sons, Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus

A. Tocoian, P. Buchan, H. Kirby, J. Soranson, M. Zamacona, R. Walley, N. Mitchell, E. Esfandiari, F. Wagner, R. Oliver

LUPUS (2015)

Article Pharmacology & Pharmacy

Advantages of a wholly Bayesian approach to assessing efficacy in early drug development: a case study

Rosalind J. Walley, Claire L. Smith, Jeremy D. Gale, Phil Woodward

PHARMACEUTICAL STATISTICS (2015)

Article Urology & Nephrology

Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy

Wim Scheele, Susan Diamond, Jeremy Gale, Valerie Clerin, Nihad Tamimi, Vu Le, Rosalind Walley, Fernando Grover-Paez, Christelle Perros-Huguet, Timothy Rolph, Meguid El Nahas

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)

Article Pharmacology & Pharmacy

Using Bayesian analysis in repeated preclinical in vivo studies for a more effective use of animals

Rosalind Walley, John Sherington, Joe Rastrick, Eric Detrait, Etienne Hanon, Gillian Watt

PHARMACEUTICAL STATISTICS (2016)

Review Obstetrics & Gynecology

The translational challenge in the development of new and effective therapies for endometriosis: a review of confidence from published preclinical efficacy studies

Nick Pullen, Claire L. Birch, Garry J. Douglas, Qasim Hussain, Ingrid Pruimboom-Brees, Rosalind J. Walley

HUMAN REPRODUCTION UPDATE (2011)

Article Public, Environmental & Occupational Health

Pooling Different Safety Data Sources: Impact of Combining Solicited and Spontaneous Reports on Signal Detection In Pharmacovigilance

Jeremy D. Jokinen, Rosalind J. Walley, Michael W. Colopy, Thomas S. Hilzinger, Peter Verdru

DRUG SAFETY (2019)

Article Medical Informatics

Reducing Patient Burden in Clinical Trials Through the Use of Historical Controls: Appropriate Selection of Historical Data to Minimize Risk of Bias

Jessica Lim, Li Wang, Nicky Best, Jeen Liu, Jiacheng Yuan, Florence Yong, Lanju Zhang, Rosalind Walley, Alice Gosselin, Robert Roebling, Kert Viele

THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2020)

Review Medical Informatics

Real-World Evidence Utilization in Clinical Development Reflected by US Product Labeling: Statistical Review

Yodit Seifu, Margaret Gamalo-Siebers, Friederike M-S Barthel, Junjing Lin, Junshan Qiu, Freda Cooner, Shiling Ruan, Rosalind Walley

THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2020)

Article Pharmacology & Pharmacy

Optimising the trade-off between type I and II error rates in the Bayesian context

Rosalind J. Walley, Andrew P. Grieve

Summary: For any decision-making study, it is important to consider the trade-off between type I and II error rates, as well as the context and prior beliefs of the study. When resources are limited, optimizing this trade-off becomes crucial, especially in the case of planned Bayesian statistical analysis.

PHARMACEUTICAL STATISTICS (2021)

Article Pharmacology & Pharmacy

From innovative thinking to pharmaceutical industry implementation: Some success stories

Rosalind Walley, Nigel Brayshaw

Summary: Successful innovation in industry involves both developing new statistical methodology and ensuring its successful implementation by enabling applied statisticians to understand and implement the new method. Advocacy and influencing stakeholders are key to gaining acceptance for the new methodology.

PHARMACEUTICAL STATISTICS (2022)

Article Chemistry, Medicinal

Designing compound subsets: Comparison of random and rational approaches using statistical simulation

Siew Kuen Yeap, Rosalind J. Walley, Mike Snarey, Willem P. van Hoorn, Jonathan S. Mason

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2007)

Article Multidisciplinary Sciences

Pharmaco-metabonomic phenotyping and personalized drug treatment

TA Clayton, JC Lindon, O Cloarec, H Antti, C Charuel, G Hanton, JP Provost, JL Le Net, D Baker, RJ Walley, JR Everett, JK Nicholson

NATURE (2006)

Review Mathematical & Computational Biology

Statistical evaluation of biomarkers as surrogate endpoints: a literature review

CJ Weir, RJ Walley

STATISTICS IN MEDICINE (2006)

Article Biochemical Research Methods

Gas chromatography/flame ionisation detection mass spectrometry for the detection of endogenous urine metabolites for metabonomic studies and its, use as a complementary tool to nuclear magnetic resonance spectroscopy

Sally-Ann Fancy, Olaf Beckonert, Gareth Darbon, Warren Yabsley, Rosalind Walley, David Baker, George L. Perkins, Frank S. Pullen, Klaus Rumpel

RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2006)

No Data Available